je.st
news
Tag: phase
Phase One Schneider Kreuznach LS 80mm f/2.8
2014-03-10 15:35:35| PC Magazine: New Product Reviews
The Phase One Schneider Kreuznach LS 80mm f/2.8 is the standard-angle lens for the Phase One 645DF+ medium format camera body; it's very sharp, but does show some barrel distortion.
Tags: phase
schneider
80mm
f28
Phase One Schneider Kreuznach LS 28mm f/4.5
2014-03-10 15:35:35| PC Magazine: New Product Reviews
The Phase One Schneider Kreuznach LS 28mm f/4.5 is an extremely sharp medium format lens with an ultra-wide field of view, but it's heavy and expensive.
ICCT provides policy update on proposed China Phase 4 fuel economy regulations
2014-03-06 13:30:19| Green Car Congress
Tags: policy
china
update
proposed
Mercks Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Nave Adults
2014-03-05 18:15:00| Merck.com - Research & Development News
Dateline City: BOSTON Merck Plans to Initiate Phase 3 Clinical Development Program in Second Half of 2014 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented data from the dose-ranging portion of an ongoing Phase 2B clinical trial of doravirine, the companys investigational next-generation, non-nucleoside reverse transcriptase inhibitor (NNRTI), at the 21st Conference on Retroviruses and Opportunistic Infections (CROI). Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639orSarra Herzog, 201-669-6570orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: study
activity
phase
adults
Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet
2014-03-04 23:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Data Presented at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Diego. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
house
study
phase
Sites : [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] next »